Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OASIS: Observational Study of LAIs In Schizophrenia

Next Previous
Trial Profile

OASIS: Observational Study of LAIs In Schizophrenia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 11 Sep 2023 According to a Alkermes media release, three posters describing the first set of results from this study evaluating the use of second-generation long-acting injectables (LAIs) in community clinics, including during the COVID-19 pandemic, presented at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville.
  • 01 Feb 2023 Status changed from active, no longer recruiting to completed.
  • 20 Sep 2022 According to a Alkermes media release, study design, interim demographics, and baseline characteristics from the trial were presented at the Psych Congress in New Orleans.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top